First Financial (NASDAQ:THFF) reported quarterly earnings of $1.27 per share. This is a 2.42 percent increase over earnings of $1.24 per share from the same period last year.
REGENXBIO Announced Interim Data from Phase II AAVIATE Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
REGENXBIO Inc. (NASDAQ:RGNX) today announced positive interim data from the Phase II AAVIATE® trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using suprachoroidal delivery.
